Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity

Michael Pavlides, Rajarshi Banerjee, Elizabeth M Tunnicliffe, Catherine Kelly, Jane Collier, Lai Mun Wang, Kenneth A Fleming, Jeremy F Cobbold, Matthew D Robson, Stefan Neubauer, Eleanor Barnes, Michael Pavlides, Rajarshi Banerjee, Elizabeth M Tunnicliffe, Catherine Kelly, Jane Collier, Lai Mun Wang, Kenneth A Fleming, Jeremy F Cobbold, Matthew D Robson, Stefan Neubauer, Eleanor Barnes

Abstract

Background & aims: The diagnosis of non-alcoholic steatohepatitis and fibrosis staging are central to non-alcoholic fatty liver disease assessment. We evaluated multiparametric magnetic resonance in the assessment of non-alcoholic steatohepatitis and fibrosis using histology as standard in non-alcoholic fatty liver disease.

Methods: Seventy-one patients with suspected non-alcoholic fatty liver disease were recruited within 1 month of liver biopsy. Magnetic resonance data were used to define the liver inflammation and fibrosis score (LIF 0-4). Biopsies were assessed for steatosis, lobular inflammation, ballooning and fibrosis and classified as non-alcoholic steatohepatitis or simple steatosis, and mild or significant (Activity ≥2 and/or Fibrosis ≥2 as defined by the Fatty Liver Inhibition of Progression consortium) non-alcoholic fatty liver disease. Transient elastography was also performed.

Results: Magnetic resonance success rate was 95% vs 59% for transient elastography (P<.0001). Fibrosis stage on biopsy correlated with liver inflammation and fibrosis (rs =.51, P<.0001). The area under the receiver operating curve using liver inflammation and fibrosis for the diagnosis of cirrhosis was 0.85. Liver inflammation and fibrosis score for ballooning grades 0, 1 and 2 was 1.2, 2.7 and 3.5 respectively (P<.05) with an area under the receiver operating characteristic curve of 0.83 for the diagnosis of ballooning. Patients with steatosis had lower liver inflammation and fibrosis (1.3) compared to patients with non-alcoholic steatohepatitis (3.0) (P<.0001); area under the receiver operating characteristic curve for the diagnosis of non-alcoholic steatohepatitis was 0.80. Liver inflammation and fibrosis scores for patients with mild and significant non-alcoholic fatty liver disease were 1.2 and 2.9 respectively (P<.0001). The area under the receiver operating characteristic curve of liver inflammation and fibrosis for the diagnosis of significant non-alcoholic fatty liver disease was 0.89.

Conclusions: Multiparametric magnetic resonance is a promising technique with good diagnostic accuracy for non-alcoholic fatty liver disease histological parameters, and can potentially identify patients with non-alcoholic steatohepatitis and cirrhosis.

Keywords: diagnostic accuracy; non-alcoholic steatohepatitis; non-invasive test; sensitivity and specificity.

© 2017 The Authors Liver International Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Study flow chart. NAFLD, non‐alcoholic fatty liver disease, MR, magnetic resonance, TE, transient elastography
Figure 2
Figure 2
Representative magnetic resonance data. Magnetic resonance data (T1, T2*, cT 1 maps and LIF scores) from patients classified using the Fatty Liver Inhibition of Progression (FLIP) algorithm as having: mild disease (top panel), significant disease/mild fibrosis (middle panel) and significant disease/advanced fibrosis (bottom panel). Red circles indicate typical regions of interest. Iron‐corrected T1 (cT 1), liver inflammation and fibrosis (LIF) scores, and corresponding transient elastography (TE) data and histological scores are included. The predefined colour scale for generating the LIF score is based on the cT 1 maps and is shown in each case [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Liver inflammation and fibrosis score for the evaluation of (A) fibrosis, (B) ballooning, (C) lobular inflammation and (D) activity. (A) There was a significant association between LIF and fibrosis (rs=.51; P<.0001). The median LIF score could differentiate (B) ballooning grades (LIF 1.2, 2.7 and 3.5 for ballooning grades 0, 1 and 2 respectively (P<.05), (C) lobular inflammation grades (LIF 1.6 vs 2.7 for lobular inflammation grade 0 vs >0) and (D) overall activity (LIF 1.3 vs 3.0 for mild (0‐1) vs significant activity.2, 3, 4 Lines and error bars indicate the median and interquartile range on all graphs [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 4
Figure 4
Liver inflammation and fibrosis score for the assessment of the total steatosis, activity and fibrosis score. There was a strong association between the liver inflammation and fibrosis score (LIF) and the overall histological severity scored by the steatosis, activity and fibrosis score (SAF; rs=.70; P<.0001) [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 5
Figure 5
Liver inflammation and fibrosis score for NAFLD classification according to the Fatty Liver Inhibition of Progression consortium algorithms. Liver inflammation and fibrosis scores (LIF) are plotted against the diagnostic categories of the Fatty Liver Inhibition of Progression (FLIP) algorithm. (A), Patients with steatosis had lower median LIF scores compared to patients with NASH (1.3 vs 3.0; P<.0001) and (B), patients with mild disease had lower median LIF scores compared to patients with severe disease (2.2 vs 3.3; P<.0001). Lines and error bars indicate the median and interquartile range on both graphs [Colour figure can be viewed at wileyonlinelibrary.com]

References

    1. Wong VW, Chu WC, Wong GL, et al. Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415.
    1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle‐aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.
    1. Hyysalo J, Mannisto VT, Zhou Y, et al. A population‐based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014;60:839–846.
    1. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 2015;148:547–555.
    1. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology. 2015;61:1547–1554.
    1. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population‐based cohort study. Gastroenterology 2005;129:113–121.
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–654. e1‐9; quiz e39‐40.
    1. Rawlins SR, Mullen CM, Simon HM, et al. Wedge and needle liver biopsies show discordant histopathology in morbidly obese patients undergoing Roux‐en‐Y gastric bypass surgery. Gastroenterol Rep (Oxf) 2013;1:51–57.
    1. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin‐18 fragments. Aliment Pharmacol Ther 2014;39:254–269.
    1. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin‐18 as a biomarker for NASH and fibrosis in patients with non‐alcoholic fatty liver disease. J Hepatol. 2014;60:167–174.
    1. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.
    1. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5‐year prospective study of 13,369 examinations. Hepatology. 2010;51:828–835.
    1. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862–1871.
    1. Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60:1920–1928.
    1. Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: a prospective study. Hepatology. 2016;63:453–461.
    1. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016;150:626–637. e7.
    1. Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol. 2016;111:986–994.
    1. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non‐invasive diagnosis of liver disease. J Hepatol. 2014;60:69–77.
    1. Piechnik SK, Ferreira VM, Dall'armellina E, et al. Shortened Modified Look‐Locker Inversion recovery (ShMOLLI) for clinical myocardial T1‐mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010;12:69.
    1. Tunnicliffe EM, Banerjee R, Pavlides M, Neubauer S, Robson MD. A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look‐Locker inversion recovery T1 (shMOLLI‐T1) in the liver. J Magn Reson Imaging 2017;45:450–462.
    1. Pavlides M, Banerjee R, Sellwood J, et al. Multi‐parametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016;64:308–315.
    1. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.
    1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
    1. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl‐eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377–384. e1.
    1. Heye T, Yang SR, Bock M, et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012;22:1224–1232.
    1. Haimerl M, Verloh N, Fellner C, et al. MRI‐based estimation of liver function: Gd‐EOB‐DTPA‐enhanced T1 relaxometry of 3T vs. the MELD score. Sci Rep 2014;4:5621.
    1. Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd‐EOB‐DTPA‐enhanced MR imaging in assessment of non‐alcoholic fatty liver disease. Eur Radiol 2014;24:959–966.
    1. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457.
    1. Wyatt J, Hubscher S, Bellamy C. Tissue Pathways for liver biopsies for the investigation of medical disease and for focal lesions. London, UK: Royal College of Pathologists; 2014.

Source: PubMed

3
Iratkozz fel